AUA 2017: Prevalence of Hormonal Abnormalities in Young Men with Erectile Dysfunction

Boston, MA ( The risk of erectile dysfunction (ED) increases with age and typically occurs in middle and older aged men. Dr. Mazur presented a study on young men referred with ED with symptoms of low testosterone. The authors aimed to describe the hormonal profiles of young men with the chief complaint of ED, hypothesizing that the majority of young men with ED will have normal hormonal evaluations.

This was a retrospective single center study of men aged 18-40 years who presented with the complaint of ED and had a hormonal evaluation from 2002- 2016 at a tertiary care institution. Data on demographics, co-morbidities, medications, and hormonal evaluations was obtained for all patients. Hypogonadism was defined as a testosterone level <200 ng/dL and hyperprolactinemia as a prolactin level >13.1 ng/mL.

A total of 2,292 relevant men were identified. The median age was 32.7 years with a larger proportion complaining of ED as they neared age 40 compared to younger ages. 43% of men were White, 8.6% Black, 4% Asian, 0.9% Hispanic, and 43.6% other or unknown. Median BMI was 26.8. Some of the men took medication on a regular basis that have been linked to ED including anti-hypertensives, antihistamines, and H2-receptor antagonists. The average total testosterone level was 368 ± 160 ng/dL. 10.6% of men had hypogonadism and 8.5% of men had hyperprolactinemia. Abnormalities of LH and FSH were noted in 10% and 9.1% of men, respectively. Regarding their ED treatment, 68.7% of men were given a phosphodiesterase type 5 inhibitor (PDE5i) and 2.4% were given alprostadil. Lastly, 12.9% of men were started on testosterone therapy.

The majority of men under age 40 with ED exhibit a normal hormonal milieu. Additionally, many men were using medications that have been linked to ED. Most men with ED were treated with a PDE5i.

Presented By: Daniel J. Mazur, Chicago, IL

Written By: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre

at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA